Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice

Dihydromyricetin is a natural bioactive flavonoid with unique GABA(A) receptor activity with a putative mechanism of action to reduce the intoxication effects of ethanol. Although dihydromyricetin's poor oral bioavailability limits clinical utility, the promise of this mechanism for the treatment of alcohol use disorder warrants further investigation into its specificity and druggable potential. These experiments investigated the bioavailability of dihydromyricetin in the brain and serum associated with acute anti-intoxicating effects in C57BL/6J mice. Dihydromyricetin (50 mg/kg IP) administered 0 or 15-min prior to ethanol (PO 5 g/kg) significantly reduced ethanol-induced loss of righting reflex. Total serum exposures (AUC0(->)24) of dihydromyricetin (PO 50 mg/kg) via oral (PO) administration were determined to be 2.5 mu M x h (male) and 0.7 mu M x h (female), while intraperitoneal (IP) administration led to 23.8-fold and 7.2- increases in AUC0(->)24 in male and female mice, respectively. Electrophysiology studies in alpha 5 beta 3 gamma 2 GABA(A) receptors expressed in Xenopus oocytes suggest dihydromyricetin (10 mu M) potentiates GABAergic activity (+43.2%), and the metabolite 4-O-methyl-dihydromyricetin (10 mu M) negatively modulates GABAergic activity (-12.6%). Our results indicate that administration route and sex significantly impact DHM bioavailability in mice, which is limited by poor absorption and rapid clearance. This correlates with the observed short duration of DHM's anti-intoxicating properties and highlights the need for further investigation into mechanism of DHM's potential anti-intoxicating properties.

Automated summary

Dihydromyricetin is a flavonoid with unique GABA(A) receptor activity that can reduce the intoxication effects of ethanol. Experimental results indicate that the administration route and sex significantly impact the bioavailability of dihydromyricetin, limiting its long-term anti-intoxicating effects.